|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
DE19756235A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756212A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
JP2002522499A
(ja)
*
|
1998-08-12 |
2002-07-23 |
スミスクライン・ビーチャム・コーポレイション |
カルシウム分解化合物
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
AU2001283139A1
(en)
*
|
2000-08-11 |
2002-02-25 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
|
BR0114323A
(pt)
|
2000-09-29 |
2003-07-01 |
Glaxo Group Ltd |
Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
EP1861359B1
(en)
*
|
2005-03-17 |
2012-11-14 |
Pfizer Inc. |
N-(n-sulfonylaminomethyl)cyclopropanecarboxamide derivatives useful for the treatment of pain
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
WO2007053498A1
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
EP2318369A1
(en)
|
2008-06-24 |
2011-05-11 |
TopoTarget A/S |
Squaric acid derivatives as inhibitors of the nicotinamide
|
|
MX2011002240A
(es)
|
2008-08-29 |
2011-04-05 |
Topotarget As |
Nuevos derivados de urea y tiourea.
|
|
WO2011006988A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
SG188367A1
(en)
|
2010-09-03 |
2013-04-30 |
Forma Tm Llc |
Novel compounds and compositions for the inhibition of nampt
|
|
EP2611778B1
(en)
|
2010-09-03 |
2015-08-05 |
Forma TM, LLC. |
Guanidine compounds and compositions for the inhibition of nampt
|
|
JP6038792B2
(ja)
|
2010-09-03 |
2016-12-07 |
フォーマ ティーエム， エルエルシー． |
癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
|
|
WO2012041873A1
(en)
*
|
2010-09-29 |
2012-04-05 |
Intervet International B.V. |
N-heteroaryl compounds
|
|
EP2640704A1
(en)
|
2010-11-15 |
2013-09-25 |
Abbvie Inc. |
Nampt inhibitors
|
|
AU2011329233A1
(en)
|
2010-11-15 |
2013-05-23 |
Abbvie Deutschland Gmbh & Co Kg |
NAMPT and ROCK inhibitors
|
|
CN103717574B
(zh)
|
2011-05-04 |
2017-02-22 |
福马Tm有限责任公司 |
用于抑制nampt的新化合物和组合物
|
|
IN2013MN02014A
(enExample)
|
2011-05-09 |
2015-06-12 |
Forma Tm Llc |
|
|
CA2873075A1
(en)
|
2012-05-11 |
2013-07-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
CA2870566A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Thiazolecarboxamide derivatives for use as nampt inhibitors
|
|
WO2013170115A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Pyridazine and pyridine derivatives as nampt inhibitors
|
|
CA2873060A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
EP2925750A1
(en)
|
2012-11-29 |
2015-10-07 |
Karyopharm Therapeutics, Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
EA201690153A1
(ru)
|
2013-07-03 |
2016-06-30 |
Кариофарм Терапевтикс, Инк. |
Замещенные бензофуранильные и бензоксазолильные соединения и их применения
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
MX2018001979A
(es)
|
2015-08-18 |
2019-04-25 |
Karyopharm Therapeutics Inc |
(s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
MA46660A
(fr)
|
2016-10-18 |
2019-08-28 |
Seattle Genetics Inc |
Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
AU2018258687C1
(en)
|
2017-04-27 |
2023-02-02 |
Seagen Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
EP3746079A1
(en)
|
2018-01-31 |
2020-12-09 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
KR102831570B1
(ko)
|
2018-05-04 |
2025-07-10 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
WO2021092322A1
(en)
|
2019-11-06 |
2021-05-14 |
Remedy Plan, Inc. |
Cancer treatments targeting cancer stem cells
|
|
CA3217380A1
(en)
|
2021-05-13 |
2022-11-17 |
Yushma Bhurruth-Alcor |
Nampt inhibitors and uses thereof
|